Skip to main content
. 2013 Dec 19;123(9):1412–1421. doi: 10.1182/blood-2013-08-523001

Figure 1.

Figure 1

Preexisting leukemic burden in the bone marrow inversely correlates with clinical response to DLI. (A) Disease burden in patients with relapsed CML before and at serial time points after DLI therapy demonstrated by both percent of bone marrow cells expressing the Philadelphia chromosome detected by FISH as well as (B) percent marrow cellularity. P < .01 for (A) and (B), Responders (circles) vs Nonresponders (triangles) using the exact Wilcoxon rank-sum test.